Advertisement

Advertisement

RIGL Stock Latest News

Rigel Pharmaceuticals Balances Breakout Growth With Caution

Company AnnouncementsRigel Pharmaceuticals Balances Breakout Growth With Caution

Rigel Pharmaceuticals’ pralsetinib shows efficacy in NSCLC clinical trial

PremiumThe Fly

Rigel Pharmaceuticals’ pralsetinib shows efficacy in NSCLC clinical trial

13d ago

Rigel’s New Olutasidenib Interaction Study Signals Long-Game Strategy for RIGL Investors

PremiumCompany Announcements

Rigel’s New Olutasidenib Interaction Study Signals Long-Game Strategy for RIGL Investors

23d ago

Rigel Pharmaceuticals’ Fast Track Ambitions Face Significant FDA Uncertainty

PremiumCompany Announcements

Rigel Pharmaceuticals’ Fast Track Ambitions Face Significant FDA Uncertainty

1M ago

Rigel Pharmaceuticals sees FY26 revenue $275M-$290M, consensus $279.31M

PremiumThe Fly

Rigel Pharmaceuticals sees FY26 revenue $275M-$290M, consensus $279.31M

1M ago

Rigel Pharmaceuticals reports Q4 EPS $13.54 with items, consensus $1.20

PremiumThe FlyRigel Pharmaceuticals reports Q4 EPS $13.54 with items, consensus $1.20

1M ago

Is RIGL a Buy, Before Earnings?

Pre-Earnings

Is RIGL a Buy, Before Earnings?

1M ago

Rigel Pharmaceuticals Appoints Michael P. Miller to Board

Company Announcements

Rigel Pharmaceuticals Appoints Michael P. Miller to Board

2M ago

Rigel Pharmaceuticals price target raised to $71 from $69 at Citi

PremiumThe Fly

Rigel Pharmaceuticals price target raised to $71 from $69 at Citi

3M ago

Rigel: Strengthening Commercial Trajectory, Clear Path to 2026 Profitability, and Advancing Pipeline Support Buy Rating

PremiumRatings

Rigel: Strengthening Commercial Trajectory, Clear Path to 2026 Profitability, and Advancing Pipeline Support Buy Rating

3M ago

Rigel Announces Strong Preliminary 2025 Results and Outlook

PremiumCompany Announcements

Rigel Announces Strong Preliminary 2025 Results and Outlook

3M ago

Rigel Pharmaceuticals sees Q4 revenue $69.8M, consensus $66.44M

PremiumThe Fly

Rigel Pharmaceuticals sees Q4 revenue $69.8M, consensus $66.44M

3M ago

Rigel Pharmaceuticals sees FY26 revenue $275M-$290M, consensus $291.58M

PremiumThe FlyRigel Pharmaceuticals sees FY26 revenue $275M-$290M, consensus $291.58M

3M ago

Rigel Pharmaceuticals Reports Promising Phase 1b Study Results

Company Announcements

Rigel Pharmaceuticals Reports Promising Phase 1b Study Results

4M ago

Rigel’s Promising Pipeline and Strategic Advancements Justify Buy Rating

Ratings

Rigel’s Promising Pipeline and Strategic Advancements Justify Buy Rating

4M ago

Rigel Pharmaceuticals announces updated data from Phase 1b study of R2891

PremiumThe Fly

Rigel Pharmaceuticals announces updated data from Phase 1b study of R2891

4M ago

Rigel Pharmaceuticals’ olutasidenib shows efficacy in Phase 2 AML trial

PremiumThe Fly

Rigel Pharmaceuticals’ olutasidenib shows efficacy in Phase 2 AML trial

5M ago

Rigel Pharmaceuticals Reports Record Q3 Revenue and Growth

PremiumCompany Announcements

Rigel Pharmaceuticals Reports Record Q3 Revenue and Growth

5M ago

Rigel Pharmaceuticals upgraded to Buy at Jefferies on strong execution

PremiumThe Fly

Rigel Pharmaceuticals upgraded to Buy at Jefferies on strong execution

5M ago

Rigel Pharmaceuticals upgraded to Buy from Hold at Jefferies

PremiumThe FlyRigel Pharmaceuticals upgraded to Buy from Hold at Jefferies

5M ago

Midday Fly By: Broader market bought on dip after tech selloff

The Fly

Midday Fly By: Broader market bought on dip after tech selloff

5M ago

Rigel Pharmaceuticals price target raised to $38 from $32 at Cantor Fitzgerald

The Fly

Rigel Pharmaceuticals price target raised to $38 from $32 at Cantor Fitzgerald

5M ago

Trending

S&P 500

―

Dow Jones

―

Nasdaq 100

―

More Trending Stocks >